Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial

Published:2015-08 Issue:8 Volume:14 Page:795-803
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference35 articles.

1. Epidemiology of Parkinson's disease;de Lau;Lancet Neurol,2006

2. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology;Suchowersky;Neurology,2006

3. Neuroprotection trials in Parkinson's disease: systematic review;Hart;Mov Disord,2009

4. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment;Ravina;Neurology,2003

5. PPAR: a therapeutic target in Parkinson's disease;Chaturvedi;J Neurochem,2008

Cited by 229 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study;Parkinsonism & Related Disorders;2024-11

2. A comprehensive review and recent advancement in the application of tannins for treating Parkinson disease;Pharmacological Research - Modern Chinese Medicine;2024-09

3. Immunomodulation as a treatment for Parkinson�s disease in current trials: a systematic review and meta-analysis;Revista de investigaci�n Cl�nica;2024-07-12

4. Supplementing Best Care with Specialized Rehabilitation Treatment in Parkinson’s Disease: A Retrospective Study by Different Expert Centers;Journal of Clinical Medicine;2024-05-20

5. Unraveling the Ties: Type 2 Diabetes and Parkinson's Disease - A Nano-Based Targeted Drug Delivery Approach;Current Diabetes Reviews;2024-05-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3